LATEST NEWS AND EVENTS

Doctor, What is Neuroendocrine Cancer?

Waiting for a download is frustrating. Imagine waiting 5+ years for a cancer diagnosis. Neuroendocrine cancer takes on average 5+ years to diagnose due to [...]

How Nuclear Technology can Beat Cancer

How nuclear medicine can beat cancer? These are extraordinary times, and patients waiting for life-changing medical treatments should not suffer. They want to know that [...]

Seeing Cancer Cells, Killing Cancer Cells

Using molecules to safely carry radioactive materials inside the human body is helping physicians get more accurate images of tumors and more effectively eliminate cancer [...]

World Theranostics Day 2021!

Today is World Theranostics Day! On this day in 1941, the first radioiodine treatment was administered and we are very eager to see what's yet [...]

  • PSMA Lu177 x Ac225

PSMA Lu-177 x Ac-225

Available since 2015, the treatment of patients with metastatic castration-resistant prostate cancer (mCRPCC) with the beta-emitter Lutetium-177 has had several early-stage dosimetry studies published, demonstrated [...]

  • Winter Newsletter is out

The Winter Newsletter is out!

Looking back at 2020 accomplishments, fundraising campaign, meeting the newcomers Ambassadors, focusing on the latest developments in the Radiotheranostics field and meeting Tom, neuroendocrine cancer [...]

  • World Cancer Day 2021

World Cancer Day 2021

Today, the Oncidium foundation unites its voice with the World Cancer Day! No matter who we are or where we live, this occasion is a [...]

  • Hopeful 2021

Hopeful 2021!

This year has shown us more than ever the importance of access, education & hope. We've adapted to new normal & witnessed once again the developments [...]

  • IBA Webinar

Webinar Theranostics and PET Imaging Diagnostics

Webinar Theranostics and PET Imaging Diagnostics by IBA RadioPharma Solutions Watch this instructive webinar on the use of PET radiopharmaceuticals in Theranostic applications. Learn more [...]

  • Theranostics continue to gain momentum

Theranostics continue to gain momentum

Article by Richard Zimmermann, President & Founder of the Oncidium foundation. Radiotheranostics are molecules that can safely carry radioactive isotopes inside targeted human tissues and [...]

  • TheraP Trial Design in Prostate Cancer

TheraP Trial Design in Prostate Cancer

Interesting interview with Pr. Michael Hofman about TheraP Trial Design Evaluating 177Lu‐PSMA‐617 Theranostic Treatment vs Cabazitaxel in Progressive Metastatic Castration‐Resistant Prostate Cancer, where results are expected [...]

  • April 2020 - Spring Newsletter

Oncidium Spring NEWSLETTER

Fresh news about Oncidium and Radiotheranostics, close up on Neuroendocrine Cancer UK, meet the Oncidium Ambassadors and much more! >> Discover the Newsletter  

Covid19 – Stay safe

Today, we would like to raise awareness of a different nature, equally important. We hope your relatives and you are well and healthy. The health [...]

World Cancer Day

The 4th of February is the World Cancer Day. Let's increase opportunities to build global awareness and impact-driven action. Keep strong, keep believing, keep going. [...]

  • How Radiotheranostics work?

How Radiotheranostics work?

Still wondering how Radiotheranostics work? Read this very interesting and accessible article by the International Atomic Energy Agency (IAEA):“It is a very efficient approach that [...]

  • Happy Thanksgiving

Happy Thanksgiving

This year, Oncidium has a lot to be thankful for! We have been able to start our activities around the promotion of Radiotheranostics. First and [...]

CONNECT WITH US

5 days ago
D-1 for the 2021 Society of Nuclear Medicine &Molecular Imaging (SNMMI) 2021 Annual Meeting! The #Oncidiumfoundation team is ready to e-meet you at our booth to exchange ideas & find synergies to further support & accelerate the development of #radiotheranostics for #cancercare. https://t.co/OzoTT8Lt4F
1 week ago
Promising results following the initial experience using Tc-PSMA led by Dr. Yehia Omar within the @NobleRegistry, potentially opening up new options for diagnosis for men with #prostatecancer in countries that have little or no access to PET/CT or PSMA-PET tracers. #NobleRegistry https://t.co/uOv6uBYu85
Noble Registry @NobleRegistry
Promising results following the initial experience using Tc-PSMA led by Dr. Yehia Omar within the #NobleRegistry, potentially opening up new options for diagnosis for men with #prostatecancer in countries that have little or no access to PET/CT or PSMA-PET tracers.
#iPSMA https://t.co/woKfJLwCj7
2 weeks ago
177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant #prostatecancer in Phase III VISION study by @Novartis
#cancercare #radiotheranostics #theranostics #radioligandtherapy #radionuclides https://t.co/m9MRjaIhoi
Jeremie Calais @CalaisJeremie
Novartis VISION trial results are out.
Huge milestone. This will pave the way for a whole new era of radiopharmaceutical theranostics.
Many more applications, indications, refinements and new targets to come.
https://t.co/uiYMjEfJFS https://t.co/taVEFHNCze